Journals / The Anatolian Journal of Cardiology / 2022 / Cilt: 26 - Sayı: 1

Change in pulmonary arterial compliance and pulmonary pulsatile stress after balloon pulmonary angioplasty

Pages
43–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results indicate that BPA decreases CPA and pulmonary pulsatile stress.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Although the underlying pathology of chronic thromboembolic pulmonary hypertension (CTEPH) is mechanical obliteration of the major pulmonary vessels, high pulsatile stress penetrating into the normal distal pulmonary microvasculature resulting from reduced pulmonary arterial compliance (CPA) may cause progressive deterioration in pulmonary hemodynamics.
📊
Key Findings & Data:Methods: In total, 26 patients with available pre- and post-BPA right heart catheterization results were included in the study.
💡
Conclusion & Impact:Conclusion: Our results indicate that BPA decreases CPA and pulmonary pulsatile stress.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Although the underlying pathology of chronic thromboembolic pulmonary hypertension (CTEPH) is mechanical obliteration of the major pulmonary vessels, high pulsatile stress penetrating into the normal distal pulmonary microvasculature resulting from reduced pulmonary arterial compliance (CPA) may cause progressive deterioration in pulmonary hemodynamics. Hypothetically, balloon pulmonary angioplasty (BPA) may be beneficial in reducing CPA and pulsatile stress in patients with CTEPH. Methods: In total, 26 patients with available pre- and post-BPA right heart catheterization results were included in the study. BPA was performed in a series of staged procedures by 2 experienced interventional cardiologists. Results: The median CPA showed a 59.2% increase (1.03 to 1.64 mL/mm Hg, p=0.005). The median pre-BPA pulsatile stress product decreased by 20.7% (4,266 to 3,380 mm Hg/min, p=0.003). A linear regression model established that the percent change in CPA after BPA accounted for 21.8% of the explained variability in the change in 6-minute walk test (p=0.009). Conclusion: Our results indicate that BPA decreases CPA and pulmonary pulsatile stress. These changes may be partly responsible for the improvement in functional capacity after BPA

🔖

Cite This Article

AKASLAN, D., ATAŞ, H., ASLANGER, E., KANAR, B. G., MUTLU, B., KOCAKAYA, D., YILDIZELİ, B. (2022). Change in pulmonary arterial compliance and pulmonary pulsatile stress after balloon pulmonary angioplasty. The Anatolian Journal of Cardiology, Cilt: 26 - Sayı: 1, 43–48. https://ajindex.com/articles/407430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017
  2. 160112. [Crossref] 2. Tan W, Madhavan K, Hunter KS, Park D, Stenmark KR. Vascular stiffening in pulmonary hypertension: cause or consequence? (2013 Grover Conference series). Pulm Circ 2014
  3. [Crossref] 3. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, et al. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry. Circ Cardiovasc Qual Outcomes 2017
  4. e004029. [Crossref] 4. Kataoka M, Inami T, Kawakami T, Fukuda K, Satoh T. Balloon Pulmonary Angioplasty (Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic Pulmonary Hypertension: A Japanese Perspective. JACC Cardiovasc Interv 2019
  5. [Crossref] 5. Kwon W, Yang JH, Park TK, Chang SA, Jung DS, Cho YS, et al. Impact of Balloon Pulmonary Angioplasty on Hemodynamics and Clinical Outcomes in Patients with Chronic Thromboembolic Pulmonary Hypertension: the Initial Korean Experience. J Korean Med Sci 2018
  6. e24. [Crossref] 6. Wang W, Wen L, Song Z, Shi W, Wang K, Huang W. Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis. Clin Cardiol 2019
  7. [Crossref] 7. Lang I, Meyer BC, Ogo T, Matsubara H, Kurzyna M, Ghofrani HA, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017
  8. 160119. [Crossref] 8. Brenot P, Jaïs X, Taniguchi Y, Garcia Alonso C, Gerardin B, Mussot S, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 2019
  9. 1802095. [Crossref] 9. Anand V, Frantz RP, DuBrock H, Kane GC, Krowka M, Yanagisawa R, et al. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience. Mayo Clin Proc Innov Qual Outcomes 2019
  10. [Crossref] 10. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al.
  11. ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC